What is Semarion?
Semarion operates at the critical intersection of advanced engineering and biological research. By developing sophisticated materials and microfabrication techniques, the company addresses fundamental bottlenecks in drug discovery and cell-based testing. Its core platform is designed to standardize and scale cell models, providing researchers with the high-fidelity data necessary to accelerate scientific breakthroughs. As a key player in the UK deeptech ecosystem, Semarion is effectively bridging the gap between academic research and commercial application, positioning itself as an essential partner for pharmaceutical and biotech organizations seeking to optimize their R&D pipelines through improved experimental precision.
How much funding has Semarion raised?
Semarion has raised a total of $6.7M across 2 funding rounds:
Angel/Seed
$2.9M
Other Financing Round
$3.8M
Angel/Seed (2022): $2.9M with participation from Martlet Capital, University of Cambridge, and Parkwalk Advisors
Other Financing Round (2026): $3.8M led by Parkwalk Advisors, Enterprize, The FSE Group, Found Capital, Cambridge Innovation Capital, Oxford Investment Opportunity Network, and Cambridge Capital Group
Key Investors in Semarion
Parkwalk Advisors
A leading investor in university spinouts, Parkwalk specializes in deeptech innovations and bridges the gap between academic research and commercial success.
Cambridge Innovation Capital
A venture investor focused on supporting entrepreneurs in life sciences and deep tech within the Cambridge ecosystem through financial backing and expert guidance.
Cambridge Capital Group
A prominent business angel network with 25 years of experience investing in high-tech startups across the UK's Golden Triangle.
What's next for Semarion?
With this major enterprise-level funding, Semarion is well-positioned to transition from its foundational research phase into a period of rapid commercial scaling. The strategic allocation of these resources will likely focus on expanding the company's manufacturing capabilities and broadening the reach of its cell-based research tools within the global market. By leveraging its strong network of university-linked investors and deeptech specialists, Semarion is poised to enhance its operational footprint, potentially entering new therapeutic areas and further refining its microfabrication processes to meet the increasing demand for high-quality, scalable biological data in the drug development lifecycle.
See full Semarion company page
